Celcuity (CELC) Secures FDA Approval for Revtorpyk in Breast Cancer Treatment
Related Stocks: CELC
Read the full articleYou might also wanna read
Celcuity Inc. (CELC) Stock: Slides 16% as FDA Clears REVTORPYK for Breast Cancer
TLDR Celcuity stock falls 16% despite FDA approval of REVTORPYK for breast cancer. FDA clears REVTORPYK as Celcuity advances targeted cancer
Celcuity Announces FDA Approval of REVTORPYKâ„¢ (gedatolisib) for the Treatment of HR+/HER2-, PIK3CA Wild-Type Locally Advanced or Metastatic Breast Cancer
REVTORPYK (gedatolisib) REVTORPYK (gedatolisib) vial and box REVTORPYK is the first and only FDA-approved therapy that inhibits all class I
Celcuity wins breast cancer nod, securing ‘differentiated foothold’ in market
Celcuity’s first approved drug, Revtorpyk, is indicated for the second-line treatment of advanced HER2- breast cancer patients without PIK3C
US FDA approves Celcuity’s breast cancer drug
By Kunal Das and Christy Santhosh July 14 (Reuters) - The U.S. FDA has approved Celcuity's drug for an advanced form of breast cancer, the r
US FDA approves Celcuity’s breast cancer drug
By Kunal Das and Christy Santhosh July 14 (Reuters) - The U.S. FDA has approved Celcuity's drug for an advanced form of breast cancer, the r
Celcuity gets FDA nod for first-in-class breast cancer drug
Celcuity gets FDA nod for first-in-class breast cancer drug Phil.Taylor Wed, 15/07/2026 - 09:10
Comments
Sign in to join the conversation.
No comments yet. Be the first.